Shenzhen Genuine Biomedical Technology

Shenzhen Genuine Biomedical Technology Co., Ltd. is a prominent Chinese biopharmaceutical company and a core R&D subsidiary of Genuine Biotech. The company is dedicated to the development and commercialization of innovative therapies for viral infections, oncology, and cerebrovascular diseases. Its most notable achievement is the development of Azvudine, the first domestically produced oral antiviral drug approved in China for both HIV-1 and COVID-19. The company's pipeline features a range of promising candidates, including next-generation long-acting HIV treatments and targeted anti-tumor agents like EGFR inhibitors and antibody-drug conjugates. Utilizing its proprietary nucleoside and XDC technology platforms, Shenzhen Genuine Biomedical Technology focuses on overcoming drug resistance and addressing significant unmet medical needs. With a strong manufacturing base and strategic partnerships, the company is positioned as a key player in the global biopharmaceutical landscape.